Quest Diagnostics partners with Universal DX for colorectal cancer blood test

Quest Diagnostics announced a strategic collaboration with Universal DX, a biotech company on a mission to transform cancer into a curable disease, designed to improve colorectal cancer screening in the United States. Under the commercial agreement between UDX and Quest, Quest plans to perform and provide clinical laboratory services to providers and patients in the United States based on UDX’s Signal-C, an advanced colorectal cancer screening blood test, assuming premarket approval of the test in the U.S. To support a submission to the FDA for premarket approval, UDX will enroll patients in a 15,000-patient study involving more than 100 investigator sites to develop clinical evidence for the test. Assuming FDA approval, Quest will have exclusive rights to provide clinical laboratory services in the U.S. UDX also announced the initial closing of its series B financing of approximately $70M from investors, including Quest Diagnostics.